{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:27:07Z","timestamp":1760016427366,"version":"3.40.4"},"reference-count":43,"publisher":"Japanese Pharmacological Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1254\/jphs.13257fp","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T23:59:25Z","timestamp":1397692765000},"page":"468-479","source":"Crossref","is-referenced-by-count":20,"title":["The Aggravation of Clozapine-Induced Hepatotoxicity by Glycyrrhetinic Acid in Rats"],"prefix":"10.1254","volume":"124","author":[{"given":"Ling-ling","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-yu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-li","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-man","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:537\u2013544.","DOI":"10.1016\/0278-5846(94)90010-8"},{"key":"2","unstructured":"2 Manceaux P, Constant E, Zdanowicz N, Jacques D, Reynaert C. Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature. Psychiatr Danub. 2011;23 Suppl 1:S15\u2013S17."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995;272:984\u2013990.","DOI":"10.1016\/S0022-3565(25)24566-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Takakusa H, Masumoto H, Mitsuru A, Okazaki O, Sudo K. Markers of electrophilic stress caused by chemically reactive metabolites in human hepatocytes. Drug Metab Dispos. 2008;36:816\u2013823.","DOI":"10.1124\/dmd.107.018002"},{"key":"5","unstructured":"5 K Linnet, OV Olesen. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos. 1997;25:1379\u20131382."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Fang J, Coutts RT, McKenna KF, Baker GB. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998;358:592\u2013599.","DOI":"10.1007\/PL00005298"},{"key":"7","unstructured":"7 Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, Midha KK. N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos. 1997;25:524\u2013527."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008;22:709\u2013724.","DOI":"10.1002\/ptr.2362"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ming LJ, Yin AC. Therapeutic effects of glycyrrhizic acid. Nat Prod Commun. 2013;8:415\u2013418.","DOI":"10.1177\/1934578X1300800335"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Kalaiarasi P, Kaviarasan K, Pugalendi KV. Hypolipidemic activity of 18<i>\u03b2<\/i>-glycyrrhetinic acid on streptozotocin-induced diabetic rats. Eur J Pharmacol. 2009;612:93\u201397.","DOI":"10.1016\/j.ejphar.2009.04.003"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Wan XY, Luo M, Li XD, He P. Hepatoprotective and anti-hepatocarcinogenic effects of glycyrrhizin and matrine. Chem Biol Interact. 2009;181:15\u201319.","DOI":"10.1016\/j.cbi.2009.04.013"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Jeong HG, You HJ, Park SJ, Moon AR, Chung YC, Kang SK, et al. Hepatoprotective effects of 18-<i>\u03b2<\/i>-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P4502E1 expression. Pharmacol Res. 2002;46:221\u2013227.","DOI":"10.1016\/S1043-6618(02)00121-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hattori M, Sakamoto T, Kobashi K, Namba T. Metabolism of glycyrrhizin by human intestinal flora. Planta Med. 1983;48:38\u201342.","DOI":"10.1055\/s-2007-969875"},{"key":"14","unstructured":"14 Hu WY, Li YW, Hou YN, He K, Chen JF, But PP, et al. The induction of liver microsomal cytochrome P450 by Glycyrrhiza uralensis and glycyrrhetinic acid in mice. Biomed Environ Sci. 1999;12:10\u201314."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Tu JH, He YJ, Chen Y, Fan L, Zhang W, Tan ZR, et al. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010;66:805\u2013810.","DOI":"10.1007\/s00228-010-0814-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tsukamoto S, Aburatani M, Yoshida T, Yamashita Y, El-Beih AA, Ohta T. CYP3A4 inhibitors isolated from Licorice. Biol Pharm Bull. 2005;28:2000\u20132002.","DOI":"10.1248\/bpb.28.2000"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Zhao K, Ding M, Cao H, Cao ZX. In vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates. J Pharm Pharmacol. 2012;64:1445\u20131451.","DOI":"10.1111\/j.2042-7158.2012.01516.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kemp DC, Brouwer KL. Viability assessment in sandwich-cultured rat hepatocytes after xenobiotic exposure. Toxicol In Vitro. 2004;18:869\u2013877.","DOI":"10.1016\/j.tiv.2004.04.014"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Fern\u00f8 J, Vik-Mo AO, Jassim G, H\u00e5vik B, Berge K, Skrede S, et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl). 2009;203:73\u201384.","DOI":"10.1007\/s00213-008-1370-x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Xie SS, Hu N, Jing XY, Liu XD, Xie L, Wang GJ, et al. Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. J Pharm Pharmacol. 2010;62:440\u2013447.","DOI":"10.1211\/jpp.62.04.0005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248\u2013254.","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Mosier KE, Song J, McKay G, Hubbard JW, Fang J. Determination of clozapine, and its metabolites, N-desmethylclozapine and clozapine N-oxide in dog plasma using high-performance liquid chromatography. J Chromatogr B. 2003;783:377\u2013382.","DOI":"10.1016\/S1570-0232(02)00655-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Liu H, Liu L, Li J, Mei D, Duan R, Hu N, et al. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with Streptozotocin-induced diabetes mellitus. Drug Metab Dispos. 2012;40:1104\u20131112.","DOI":"10.1124\/dmd.111.043513"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Bendriss EK, Markoglou N, Wainer IW. High-performance liquid chromatography assay for simultaneous determination of dextromethorphan and its main metabolites in urine and in microsomal preparations. J Chromatogr B Biomed Sci Appl. 2001;754:209\u2013215.","DOI":"10.1016\/S0378-4347(00)00609-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Zhu Q, Liao J, Xie L, Wang GJ, Liu XD. Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica. 2009;39:293\u2013301.","DOI":"10.1080\/00498250802709428"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Yamada S, Shiohira H, Yasui-Furukori N, Tateishi T, Akamine Y, Uno T. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers. Eur J Clin Pharmacol. 2013;69:1423\u20131428.","DOI":"10.1007\/s00228-013-1480-1"},{"key":"27","unstructured":"27 Gauch R, Michiaelis W. The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo-[b,c][1,4]diazepine(clozapine) in mice, dogs and human subjects. Farmaco. 1971;26:667\u2013681."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Shen C, Zhang G, Qiu H, Meng Q. Acetaminophen-induced hepatotoxicity of gel entrapped rat hepatocytes in hollow fibers. Chem Biol Interact. 2006;162:53\u201361.","DOI":"10.1016\/j.cbi.2006.05.005"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Lu Y, Meng Q, Zhang G, Bei X. Clozapine-induced hepatotoxicity in rat hepatocytes by gel entrapment and monolayer culture. Toxicol In Vitro. 2008;22:1754\u20131760.","DOI":"10.1016\/j.tiv.2008.08.002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013;41:651\u2013658.","DOI":"10.1124\/dmd.112.050484"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Rousu T, Tolonen A. Characterization of cyanide-trapped methylated metabonates formed during reactive drug metabolite screening in vitro. Rapid Commun Mass Spectrom. 2011;25:1382\u20131390.","DOI":"10.1002\/rcm.5005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Tugnait M, Hawes EM, McKay G, Eichelbaum M, Midha KK. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem Biol Interact. 1999;118:171\u2013189.","DOI":"10.1016\/S0009-2797(99)00006-X"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Morgan ET, MacGeoch C, Gustafsson JA. Hormonal and developmental regulation of expression of the hepatic microsomal steroid 16 alpha-hydroxylase cytochrome P-450 apoprotein in the rat. J Biol Chem. 1985;260:11895\u201311898.","DOI":"10.1016\/S0021-9258(17)38963-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica. 2000;30:1131\u20131152.","DOI":"10.1080\/00498250010021684"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Lewis DF. Cytochromes P450: structure, function and mechanism. London: Taylor &amp; Francis; 1996.","DOI":"10.1201\/9781482272772"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Bun H, Disdier B, Aubert C, Catalin J. Interspecies variability and drug interactions of clozapine metabolism by microsomes. Fundam Clin Pharmacol. 1999;13:577\u2013581.","DOI":"10.1111\/j.1472-8206.1999.tb00364.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Peters JM, Morishima H, Ward JM, Coakley CJ, Kimura S, Gonzalez FJ. Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. Toxicol Sci. 1999;50:82\u201389.","DOI":"10.1093\/toxsci\/50.1.82"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Li F, Lu J, Ma X. Profiling the reactive metabolites of xenobiotics using metabolomic technologies. Chem Res Toxicol. 2011;24:744\u2013751.","DOI":"10.1021\/tx200033v"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Wen B, Ma L, Nelson SD, Zhu M. High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry. Anal Chem. 2008;80:1788\u20131799.","DOI":"10.1021\/ac702232r"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Kellner M, Wiedemann K, Krieg JC, Berg PA. Toxic hepatitis by clozapine treatment. Am J Psychiatry. 1993;150:985\u2013986.","DOI":"10.1176\/ajp.150.6.985b"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1163\u20131166.","DOI":"10.1016\/j.pnpbp.2006.03.014"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology. 1997;112:1707\u20131709.","DOI":"10.1016\/S0016-5085(97)70054-4"},{"key":"43","unstructured":"43 Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale. 2002;28:542\u2013551."}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/124\/4\/124_13257FP\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:56:37Z","timestamp":1746186997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/124\/4\/124_13257FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.13257fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"type":"print","value":"1347-8613"},{"type":"electronic","value":"1347-8648"}],"subject":[],"published":{"date-parts":[[2014]]}}}